Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received 510(k) clearance (k191832) for its novel push-button needle.
The company which recently raised $18 million, has a connected device that is approved for Medicare coverage of psoriasis, while its smartphone app offers opportunities for engaging patients beyond treatment.
Financing Round Led by Questa Capital to Fuel Commercialization of ControlRad Trace Mobile C-arm Radiation Reduction Technology
The CMS has issued a decision granting reimbursement for procedures with Clarify Medical’s Clarify Home light therapy system for psoriasis treatment under the agency’s National Coverage Determination.
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received a second 510(k) clearance (K181895) for its new Kurin® PIV18 peripheral IV configuration with an extension set, which can be used for infusion.
Kurin, Inc. Announces Clinical Results on Kurin® Efficacy from Central Texas Veterans Health Care System
Kurin, Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the Temple VA Hospital in Temple, TX, presented their findings comparing results of Kurin and Magnolia Medical’s Steripath at the recent Southwest Association of Clinical Microbiology.
Spinal Singularity announced that the company was awarded a Phase II SBIR grant from the National Institute of Health (NIH). The grant will provide approximately $1.5 Million in non-dilutive funding to continue clinical development of the Connected Catheter 2P (C2P).